The debt payoff removes interest expense and restrictive covenants, improving financial flexibility for a pre-commercial biotech. Monitor next earnings for cash runway extension and potential FFO/EBITDA improvement. The stock's $1.8B market cap makes this ~3% of enterprise value — credit-positive catalyst for preferred holders if any, modest positive for common.
Price Chart
Executive Summary
Viridian Therapeutics voluntarily prepaid and terminated its $300M credit facility with Hercules Capital, paying off all ~$55.1M outstanding principal, interest and fees on May 27, 2026. This eliminates all debt covenants and floating-rate interest obligations (~8.95%-9.45%), removing leverage risk and strengthening the balance sheet ahead of potential regulatory milestones.
Key Facts
- Viridian prepaid ~$55.1M to fully satisfy and terminate the Hercules Capital Loan Agreement on May 27, 2026
- The loan facility provided up to $300M; Viridian had borrowed $50M under it
- Interest rate was the greater of 8.95% and Prime Rate + 1.45%, capped at 9.45%
- Interest-only payments were due through October 2029 (or 2030 with milestones) — now entirely removed
- All covenants, debts, and liabilities under the Loan Agreement are discharged in full
Financial Impact
Prepaid ~$55.1M in aggregate debt, eliminating floating-rate interest expense at 8.95%-9.45% per annum on $50M principal, and removing all debt-related covenants
Risk Factors
- The $55.1M cash used for prepayment reduces available cash reserves, potentially affecting runway length
- Pre-revenue biotech (clinical-stage) still needs to fund R&D and commercialization from remaining cash; no top-line revenue reported in this filing
- No details on Viridian's remaining cash position or pro-forma balance sheet provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-245186 |
| Document: 0001193125-26-245186-index-headers.html | 0001193125-26-245186 |
| Document: 0001193125-26-245186-index.html | 0001193125-26-245186 |
| Document: 0001193125-26-245186.txt | 0001193125-26-245186 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $22.51 $22.96 | ▲ +2.00% | ▲ +1.40% | $23.34 (+3.69%) |
May 28, 2026 21w ago | 8-K | $17.62 $18.79 | ▲ +6.64% | ▲ +8.43% | $23.34 (+32.46%) |
May 26, 2026 22w ago | 8-K | $17.26 $17.39 | ▲ +0.75% | ▲ +2.65% | $23.34 (+35.23%) |
May 8, 2026 24w ago | 424B5 | $17.20 $16.31 | ▲ +5.17% | ▲ +4.87% | $23.34 (−35.70%) |
May 5, 2026 24w ago | 424B5 | $17.53 $16.35 | ▼ −6.73% | ▼ −9.51% | $23.34 (+33.14%) |
May 5, 2026 25w ago | 8-K | $18.75 $15.87 | ▼ −15.36% | ▼ −20.31% | $23.34 (+24.48%) |
Apr 17, 2026 27w ago | DEFA14A | $14.80 $17.43 | ▲ +17.77% | ▲ +12.40% | $23.34 (+57.70%) |
Feb 26, 2026 34w ago | 8-K | $29.49 $28.20 | ▼ −4.37% | ▲ +2.03% | $23.34 (−20.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers